Axios Pro Rata: Keytruda corollary | Axios Pro Rata Summary

1. Key Themes

Theme 1: The Coming Retail Private Equity Liquidity Crisis

The Trump administration is opening private equity to retail investors via two simultaneous policy shifts — lowered accreditation standards and 401(k) access to alternatives — but the structural illiquidity of private equity creates a foreseeable mismatch with retail investor expectations.

"When private equity becomes more available to retail investors, it's likely to feature the same sorts of redemption limitations that are bedeviling retail investors in private credit. This is a predictable car crash, but no one is even checking the brakes."

"Retail investors, in general, expect liquidity-on-demand. Even from their retirement funds (albeit with a major tax penalty). Private equity, however, is an illiquid asset class."

Theme 2: Private Credit Stress Is Already Materializing — Right Now

This isn't a future risk; it's a present one. Multiple major private credit managers have already been forced to enforce redemption limits, providing a live case study for what will likely repeat in private equity.

"Both Apollo and Ares enforced redemption limits this week, following similar moves by firms like Blue Owl and Cliffwater. Redemption limits are a feature, not a bug, designed to stop funds from collapsing from the equivalent of a bank run."

"Jefferies has been central to investor concerns over private credit, due to its exposure to the First Brands bankruptcy, driving down its share price to two year lows."

Theme 3: Pharma Patent Cliffs Are Driving a Big-Pharma M&A Wave

Merck's Keytruda losing patent protection in 2028 is forcing it into a multi-billion dollar acquisition spree to replace revenue. This is a structural, time-bound investment theme with predictable deal flow as other large-cap pharma faces similar cliffs.

"The path to patent cliffs is paved with deals. Merck now has announced three large acquisitions in the past year, all in preparation of Keytruda coming off patent in 2028. The others were Verona Pharma ($10 billion) and Cidara Therapeutics ($9.2 billion)."

Theme 4: AI and Defense Infrastructure Attract Robust Venture Capital

The deal flow shows concentrated capital moving into AI-adjacent infrastructure — including power delivery for AI data centers, observability software, chip design, and defense electronics — signaling institutional conviction in picks-and-shovels AI plays.

"Epic Microsystems, a Morgan Hill, Calif.-based developer of power delivery solutions for AI infrastructure, raised $21m in Series A funding. Samsung Catalyst Fund led, joined by Intel Capital."

"Normal Computing, an NYC-based maker of software for chip design and thermodynamic computing chips, raised $50m. Samsung Catalyst Fund led."

"Arxis, a Connecticut-based defense electronics maker owned by Arcline, filed for an IPO that Renaissance Capital estimates could raise $400m. It reports $46m of net income on $1.59b of revenue for 2025."

Theme 5: Agtech and Biotech Attract Landmark Growth Capital

Halter's $220M Series E at a $2B valuation — led by Founders Fund for smart cow collars — signals that frontier agtech has arrived as a serious venture category. Meanwhile, universal vaccine development is attracting both institutional and high-profile individual backers.

"Halter, a New Zealand-based developer of smart cow collars, raised $220m in Series E funding at a $2b post-money valuation. Founders Fund led, joined by Bessemer Venture Partners, DCVC, Bond, NewView, Ubiquity, Promus, and Icehouse Ventures."

"Centivax, developer of a universal flu vaccine, raised $37m. Structure Fund led, joined by Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Patrick and John Collison."

2. Contrarian Perspectives

Semi-Liquid PE Products Won't Solve the Retail Mismatch — They'll Make It Worse

The industry's proposed solution — semi-liquid PE products with some private credit or public equities mixed in — sounds like a fix but is likely to deepen the confusion and ultimately the damage for retail investors who still won't understand the constraints.

"To prevent pitchforks, private equity execs have discussed creating semi-liquid options for individual retail investors and 401(k) plans. Maybe with some private credit or public equities mixed in so there could be quicker cash-flows."

The article's framing makes clear this is a cosmetic fix: the underlying asset remains illiquid, and the private credit precedent shows these structures break under redemption pressure. Apollo, Ares, Blue Owl, and Cliffwater have all recently been forced to enforce redemption limits — the very structures meant to protect against this.

Accreditation Standards Were Never Really About Sophistication — They Were About Wealth as a Loss Buffer

The standard pro-retail-access argument assumes reducing accreditation thresholds democratizes investment. Primack reframes it: the standards were never truly about financial sophistication at all.

"These are designed to ensure that individual investors are 'sophisticated' enough to invest in high-risk asset classes, but in practice are more about ensuring that the investors are rich enough to afford losses."

This is a non-obvious read: the policy debate is framed around access and fairness, but the practical protection was always the ability to absorb losses — not investment knowledge.

401(k) Managers Are Unprepared for the Alternatives Mandate Being Handed to Them

A widely-cited upside of the 401(k) rule change is that professional managers will bring discipline to retail alternatives exposure. Primack challenges this directly.

"One can hope that 401(k) managers will be more circumspect, but few current ones have requisite private equity experience."

This is critical for entrepreneurs and investors building in the wealth-tech and retirement-infrastructure space: the distribution channel being opened is also one of the least prepared to manage what's flowing through it.

3. Companies Identified

Merck (NYSE: MRK)

Description: Global pharmaceutical giant
Why mentioned: Acquiring Terns Pharmaceuticals for ~$6.7B; third large deal in a year to offset Keytruda patent expiration in 2028
Quote: "The path to patent cliffs is paved with deals. Merck now has announced three large acquisitions in the past year, all in preparation of Keytruda coming off patent in 2028."

Terns Pharmaceuticals (Nasdaq: TERN)

Description: Cancer biotech developing oral treatments for blood and bone cancers
Why mentioned: Acquisition target; lead candidate is a Phase 1/2 pill for chronic myeloid leukemia
Quote: "Merck will pay $53 per Terns share, representing 6% premium on yesterday's closing price and a 42% premium to the 90-day volume-weighted average."

Apollo Global Management

Description: Major alternative asset manager
Why mentioned: Enforced redemption limits on its retail-facing private credit products this week, illustrating systemic stress
Quote: "Both Apollo and Ares enforced redemption limits this week, following similar moves by firms like Blue Owl and Cliffwater."

Ares Management

Description: Major alternative asset manager
Why mentioned: Also enforced redemption limits this week; separately planning to launch an auction for pharma consulting firm The Lockwood Group
Quote: "Both Apollo and Ares enforced redemption limits this week."

Halter

Description: New Zealand-based developer of smart cow collars for livestock management
Why mentioned: Raised $220M Series E at $2B valuation, led by Founders Fund — a landmark agtech round
Quote: "Halter, a New Zealand-based developer of smart cow collars, raised $220m in Series E funding at a $2b post-money valuation."

Dash0

Description: NYC-based observability startup
Why mentioned: Raised $110M at a $1B valuation, led by Balderton Capital — significant milestone for infrastructure software
Quote: "Dash0, a NYC-based observability startup, raised $110m at a $1b valuation."

Normal Computing

Description: NYC-based maker of software for chip design and thermodynamic computing chips
Why mentioned: Raised $50M led by Samsung Catalyst Fund, with participation from Micron Ventures — strategic hardware investors signaling conviction
Quote: "Normal Computing...raised $50m. Samsung Catalyst Fund led, joined by Galvanize, Brevan Howard Macro Venture Fund, ArcTern Ventures, Celesta Capital, Drive Capital, First Spark Ventures, and Micron Ventures."

Centivax

Description: Developer of a universal flu vaccine
Why mentioned: Raised $37M including from Patrick and John Collison; high-profile biotech bet on universal vaccination platform
Quote: "Centivax, developer of a universal flu vaccine, raised $37m. Structure Fund led, joined by Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Patrick and John Collison."

SpaceX

Description: Elon Musk's private space and satellite company
Why mentioned: Reported to potentially file for IPO as early as this week
Quote: "SpaceX may file for an IPO as early as this week, per The Information."

Arxis

Description: Connecticut-based defense electronics manufacturer, owned by Arcline
Why mentioned: Filed for IPO estimated to raise $400M; notable profitability with $46M net income on $1.59B revenue for 2025
Quote: "Arxis...filed for an IPO that Renaissance Capital estimates could raise $400m. It reports $46m of net income on $1.59b of revenue for 2025."

Jefferies

Description: U.S. investment bank
Why mentioned: Share price at two-year lows due to private credit exposure; briefly spiked on takeover rumors from Japan's SMFG before cooling
Quote: "Jefferies has been central to investor concerns over private credit, due to its exposure to the First Brands bankruptcy, driving down its share price to two year lows."

Amazon (Nasdaq: AMZN)

Description: Global technology and e-commerce giant
Why mentioned: Acquired Fauna Robotics, a humanoid robotics developer — signals continued push into robotics
Quote: "Amazon acquired Fauna Robotics, an NYC-based humanoid robotics developer that raised over $16m in seed funding from Kleiner Perkins, Bluebirds Capital, and Quiet Capital."

Kleiner Perkins

Description: Storied Silicon Valley venture capital firm
Why mentioned: Raised $1B for its 22nd early-stage fund and $2.5B for a growth fund — major fundraising signal
Quote: "Kleiner Perkins raised $1b for its 22nd early-stage fund and $2.5b for a growth fund."

Brookfield Asset Management / La Caisse

Description: Major global alternative asset managers
Why mentioned: Agreed to acquire Canadian renewables company Boralex for C$9B — large-scale renewables conviction
Quote: "Brookfield Asset Management and La Caisse agreed to acquire Boralex (TSX: BLX), a Canadian renewables company, for C$9b."

Epic Microsystems

Description: Developer of power delivery solutions for AI infrastructure
Why mentioned: Raised $21M Series A led by Seligman Ventures with Intel Capital — picks-and-shovels AI infrastructure play
Quote: "Epic Microsystems, a Morgan Hill, Calif.-based developer of power delivery solutions for AI infrastructure, raised $21m in Series A funding. Seligman Ventures led, joined by Intel Capital."

Mirage (Captions app)

Description: Maker of the Captions video editing app
Why mentioned: Raised $75M in growth funding from General Catalyst — AI-powered consumer video tools gaining scale
Quote: "Mirage, maker of the Captions video editing app, raised $75m in growth funding from General Catalyst."

4. People Identified

Patrick Collison and John Collison

Description: Co-founders of Stripe
Why mentioned: Personal investors in Centivax's $37M universal flu vaccine round — notable signal of tech founders placing biotech bets
Quote: "Centivax, developer of a universal flu vaccine, raised $37m. Structure Fund led, joined by Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Patrick and John Collison."

Dan Gilbert

Description: Entrepreneur and majority owner of Cleveland's WNBA franchise
Why mentioned: Leads investor group for Cleveland's WNBA team; Monarch Collective joined as an investor, with team play expected in 2028
Quote: "Monarch Collective joined the investor group for Cleveland's WNBA franchise, which is majority owned by Dan Gilbert and expects to begin play in 2028."

Spencer Applebaum and Shayon Sengupta

Description: Newly promoted general partners at Multicoin Capital
Why mentioned: Elevated to GPs and co-heads of venture — leadership transition at a prominent crypto-native VC firm
Quote: "Multicoin Capital promoted Spencer Applebaum and Shayon Sengupta to general partners and co-heads of venture."

5. Operating Insights

PE Firms Are Designing "Semi-Liquid" Products as a Distribution Mechanism — Not a Risk Solution

Entrepreneurs and fund managers building retail alternative investment products need to understand the structural tension: these products are designed to manage distribution optics, not genuinely resolve the illiquidity mismatch. Anyone building in the alt-distribution space (feeder funds, wealth platforms, 401(k) integration tech) should architect redemption management as a core product feature from day one.

"Private equity execs have discussed creating semi-liquid options for individual retail investors and 401(k) plans. Maybe with some private credit or public equities mixed in so there could be quicker cash-flows."

The "Financial Advisor Push" Is a Key Distribution Risk to Model For

Retail exposure to private markets won't come primarily from self-directed investors — it will come through financial advisors who are incentivized by product commissions. Operators in fintech, compliance, and wealth management should expect that advisor-driven mis-selling will be the dominant liability vector.

"That will be cold comfort to retail investors who are sure to be inundated with advertisements for private equity investments, or pushed into them by financial advisors who covet new products with big promises."

Patent Cliff M&A Is Playbook-Predictable — Position Early in the Target Stack

Merck's three deals in twelve months — Terns ($6.7B), Verona Pharma ($10B), and Cidara Therapeutics ($9.2B) — form a clear pattern. Biotech founders with late-stage or near-commercial oncology and specialty pharma assets should understand that large-cap pharma is in aggressive acquisition mode before 2028 Keytruda patent expiry. This creates near-term exit clarity for the right assets.

"Merck now has announced three large acquisitions in the past year, all in preparation of Keytruda coming off patent in 2028."

6. Overlooked Insights

Futurepresent's $300M Debut Fund Signals a Generational Shift at Pre-Seed

A brand-new firm raising $300M for its first fund — at the pre-seed and seed stage — is exceptional, especially with a team drawing from General Catalyst and Cherry Ventures. This scale at inception suggests LPs are placing bets on emerging manager pedigree over track record, which has meaningful implications for both founders seeking new capital relationships and for the competitive dynamics of early-stage funding.

"Futurepresent, a new pre-seed and seed-stage firm, raised $300m for its debut fund. Its founding team includes former General Catalyst and Cherry Ventures partners."

Victory Capital's Withdrawal Clears a Rare Contested-Bid Path for General Catalyst in Asset Management

General Catalyst, alongside Trian Fund Management, now has a clear path to acquiring Janus Henderson Group after Victory Capital withdrew its $8.6B offer. A leading venture firm acquiring a $400B+ AUM public asset manager would represent an unprecedented convergence of venture and traditional asset management — a structural market shift worth watching closely.

"Victory Capital withdrew its $8.6b takeover offer for Janus Henderson Group, clearing the path for a rival bid from General Catalyst and Trian Fund Management."